TheBankTodayTheBankTodayTheBankToday
Notification Show More
Font ResizerAa
  • Home
  • Banking
  • Credit Cards
  • Loans
  • Personal Finance
  • Guides
  • Latest Updates
  • Compare Credit Cards
Reading: Wockhardt Shares Soar 10% after Breakthrough in Phase 3 Trial
Share
Font ResizerAa
TheBankTodayTheBankToday
  • Home
  • Banking
  • Credit Cards
  • Loans
  • Personal Finance
  • Guides
  • Latest Updates
  • Compare Credit Cards
Search
  • Home
  • Banking
  • Credit Cards
  • Loans
  • Personal Finance
  • Guides
  • Latest Updates
  • Compare Credit Cards
Have an existing account? Sign In
Follow US

Home » Important

Stock Market img
Important

Wockhardt Shares Soar 10% after Breakthrough in Phase 3 Trial

Takendra Verma
Last updated: 31/01/2025 6:15 PM
Takendra Verma
Published: 31/01/2025
Share
SHARE

On Friday, shares of Wockhardt Limited, a pharmaceutical company, hit a 10% upper circuit in the stock market.

Contents
Key Reasons for the Stock Price IncreaseFuture Plans and Financial PerformanceShareholding Pattern

The stock closed at ₹1,415.60, marking a rise of ₹128.65 from its previous closing of ₹1,286.95. Earlier in February 2024, the stock had hit its 52-week low at ₹421, making this a significant recovery.

Key Reasons for the Stock Price Increase

Wockhardt’s flagship product, Zaynich, has shown outstanding results in its Phase 3 trial, achieving 96.8% efficacy.

The company announced in a stock exchange filing that Zaynich could play a critical role in treating urinary tract infections caused by multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens, including Enterobacter and Pseudomonas aeruginosa.

The Phase 3 trial included 530 patients across regions like the US, Europe, Latin America, China, and India, highlighting the drug’s global potential.

Future Plans and Financial Performance

Wockhardt’s achievement makes it one of the few Indian pharmaceutical companies capable of developing and marketing a global antibiotic.

The company plans to file a New Drug Application with the US FDA and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA).

Financially, the company recorded strong growth in the first half of FY 2024-25 (April–September).

Its EBITDA grew by 112% year-on-year (YoY) to ₹239 crore, while revenue increased by 10%, reaching ₹1,565 crore compared to ₹1,420 crore in the same period last year.

Shareholding Pattern

Promoters currently hold a 49.09% stake in Wockhardt Limited, while the public owns the remaining 50.91%

You Might Also Like

SEBI Eases FPI KYC Rules (Reviews Extended Up to 8 Years)
Pension Risk for Govt Employees Even After 20 Years (See Details)
Infosys Raises Fresher Salaries Up to Rs21 lakh
India Nepal Bhutan Travel Rules: New ID Proof Required
Gujarat Government Raises DA by 3% Ahead of Diwali
Share This Article
Facebook Email Print
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Difference Between NEFT and RTGS

Get Latest Updates

Important banking and money updates, delivered without the clutter.
Thank you! You are subscribed. Please check your inbox for the welcome email.

Popular Updates

IRCTC Maharashtra Tour result
IRCTC Mauritius Tour Package (8 Days in December)
20/11/2026
sebi1 1
SEBI Foreign Portfolio Investor Rules may get Easier
20/11/2026
UPI Tap and Pay feature being used with an NFC-enabled smartphone and POS terminal
B2B UPI Transactions may get Flat ₹5 Fee
20/11/2026
railway 2
Indian Railways Group Booking Rules (No Berth Limit Now)
20/11/2026
Motorola Edge 70 Neo
Motorola Edge 70 Neo India Launch on November 24
20/11/2026

Tags

  • SBI
  • HDFC Bank
  • Bank Of Baroda
  • Central Bank
  • Central Bank Of India
  • register mobile number
  • Pan Card
  • What is Bank?
  • SBI Personal Loan
  • check bank balance

TheBankToday

TheBankToday publishes practical banking, personal-finance and financial-news explainers to help readers understand important updates and services.
Quick Links
  • About
  • Contact
  • Disclaimer
  • Join Us
  • T&C
  • Privacy Policy
  • Customize Interests
Important Links
  • Advertise With Us
  • Advertising Policy
  • Cookie Policy
  • Corrections Policy
  • Editorial Policy
  • Fact-Checking Policy
  • Grievance Redressal

Subscribe Us

Subscribe to our newsletter to get our newest articles instantly!

Thank you! You are subscribed. Please check your inbox for the welcome email.
© 2026 TheBankToday. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?